Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital)

N/A

Report date: 2024/09/18 10:05:24

Base Information

Drug NameAnti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital)
Drug Alias NameAnti CD20/CD30 chimeric antigen receptor T cell therapy (Shanghai First Song Biotechnology)Anti CD30/CD20 chimeric antigen receptor T cell therapy (Shanghai First Song Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20Anti-Tumor necrosis factor receptor superfamily member 8
TargetsB-lymphocyte antigen CD20Tumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, B-CellLymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Tongji Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Tongji HospitalShanghai First Song Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphomaLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A